CA2984637A1 - Injectable depot formulations - Google Patents

Injectable depot formulations

Info

Publication number
CA2984637A1
CA2984637A1 CA2984637A CA2984637A CA2984637A1 CA 2984637 A1 CA2984637 A1 CA 2984637A1 CA 2984637 A CA2984637 A CA 2984637A CA 2984637 A CA2984637 A CA 2984637A CA 2984637 A1 CA2984637 A1 CA 2984637A1
Authority
CA
Canada
Prior art keywords
kinase inhibitor
syringe
composition
subject
needle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2984637A
Other languages
English (en)
French (fr)
Inventor
Paul Ashton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyepoint Pharmaceuticals US Inc
Original Assignee
Psivida US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psivida US Inc filed Critical Psivida US Inc
Publication of CA2984637A1 publication Critical patent/CA2984637A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2984637A 2015-05-05 2016-05-05 Injectable depot formulations Abandoned CA2984637A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562157257P 2015-05-05 2015-05-05
US62/157,257 2015-05-05
PCT/US2016/030912 WO2016179357A1 (en) 2015-05-05 2016-05-05 Injectable depot formulations

Publications (1)

Publication Number Publication Date
CA2984637A1 true CA2984637A1 (en) 2016-11-10

Family

ID=57218334

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2984637A Abandoned CA2984637A1 (en) 2015-05-05 2016-05-05 Injectable depot formulations

Country Status (10)

Country Link
US (1) US20160324836A1 (enExample)
EP (1) EP3291812B1 (enExample)
JP (1) JP2018520093A (enExample)
CN (1) CN107530334A (enExample)
AU (1) AU2016258001B2 (enExample)
BR (1) BR112017023762A2 (enExample)
CA (1) CA2984637A1 (enExample)
MX (1) MX385405B (enExample)
RU (1) RU2017137763A (enExample)
WO (1) WO2016179357A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107278151A (zh) 2014-12-15 2017-10-20 约翰霍普金斯大学 舒尼替尼制剂及其在治疗青光眼中的使用方法
BR112018009644A2 (pt) 2015-11-12 2018-11-06 Graybug Vision Inc micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
JP7217022B2 (ja) 2017-03-23 2023-02-02 グレイバグ ビジョン インコーポレイテッド 眼障害の治療のための薬物及び組成物
CA3057875A1 (en) 2017-05-10 2018-11-15 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
CN114245737A (zh) * 2019-06-11 2022-03-25 司斐股份有限公司 微乳剂组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
CN101890018B (zh) * 2009-05-22 2014-06-18 中国科学院化学研究所 一种酪氨酸蛋白激酶抑制剂及其制备方法
WO2013000909A1 (en) * 2011-06-28 2013-01-03 Bayer Intellectual Property Gmbh Topical ophthalmological pharmaceutical composition containing sorafenib
CN104204804B (zh) * 2011-11-11 2016-09-28 因特利凯有限责任公司 激酶抑制剂的组合及其用途
AR089248A1 (es) * 2011-12-14 2014-08-06 Abbvie Inc Composiciones que contienen inhibidores de quinasas

Also Published As

Publication number Publication date
AU2016258001B2 (en) 2020-06-04
WO2016179357A1 (en) 2016-11-10
EP3291812A4 (en) 2019-01-09
MX2017014084A (es) 2018-06-20
MX385405B (es) 2025-03-18
US20160324836A1 (en) 2016-11-10
EP3291812B1 (en) 2021-09-01
CN107530334A (zh) 2018-01-02
BR112017023762A2 (pt) 2018-07-31
RU2017137763A (ru) 2019-06-05
EP3291812A1 (en) 2018-03-14
AU2016258001A1 (en) 2017-11-09
JP2018520093A (ja) 2018-07-26
RU2017137763A3 (enExample) 2019-08-21

Similar Documents

Publication Publication Date Title
JP7571171B2 (ja) 翼状片を治療するための組成物及び方法
JP6861764B2 (ja) 軸索再生および神経機能を促進するための方法および組成物
EP3291812B1 (en) Injectable depot formulations
US10617735B2 (en) Methods and compositions for preserving retinal ganglion cells
CN101443004B (zh) 用于与血管通透性有关的疾病或病症的制剂
DK1848431T3 (en) LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
AU2024219639A1 (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
KR20160135372A (ko) 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물
KR20100055482A (ko) 안질환 또는 안이상의 치료를 위한 제제
KR101877041B1 (ko) 혈관 과투과성과 부종 및 이로부터 발생하는 다른 부작용을 저해하는 방법
CN102695511A (zh) 抑制眼部瘢痕形成的转化生长因子-β受体抑制剂的用途
BR112018014467A2 (en) drug-antibody synergism technology for disease treatment
Guo et al. Pirfenidone induces G1 arrest in human Tenon's fibroblasts in vitro involving AKT and MAPK signaling pathways
TW201639569A (zh) 徐放性醫藥組成物
US20180009758A1 (en) Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
Kuerten et al. Transplantation of PEDF-transfected pigment epithelial cells inhibits corneal neovascularization in a rabbit model
JPWO2016047647A1 (ja) 角膜厚調節剤
EP2671589A1 (en) Medicinal agent for prevention or treatment of diseases associated with intraocular neovascularization and/or intraocular vascular hyperpermeability
US20170342033A1 (en) Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
US20160376239A1 (en) N-Acylalkyl Prodrugs of Multi-Tyrosine Kinase Inhibitors and Methods of Use
KR20100051811A (ko) 눈에 수용체 티로신 키나제 저해(ｒｔｋｉ) 화합물을 전달하기 위한 약제학적 제제
CN115867264A (zh) 局部眼科组合物和治疗异常血管新生的方法
US10464902B1 (en) Multi-tyrosine kinase inhibitors derivatives and methods of use
US11623917B2 (en) Multi-tyrosine kinase inhibitors derivatives and methods of use
RU2732407C1 (ru) Фармацевтическая композиция, содержащая палоносетрон в качестве активного ингредиента

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190429

FZDE Discontinued

Effective date: 20211101